JP7624388B2 - アルギナーゼ1ポリペプチド - Google Patents

アルギナーゼ1ポリペプチド Download PDF

Info

Publication number
JP7624388B2
JP7624388B2 JP2021516368A JP2021516368A JP7624388B2 JP 7624388 B2 JP7624388 B2 JP 7624388B2 JP 2021516368 A JP2021516368 A JP 2021516368A JP 2021516368 A JP2021516368 A JP 2021516368A JP 7624388 B2 JP7624388 B2 JP 7624388B2
Authority
JP
Japan
Prior art keywords
polypeptide
cells
arginase
composition
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501046A5 (cg-RX-API-DMAC7.html
JP2022501046A (ja
Inventor
ハルド アンデルセン,マッズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2022501046A publication Critical patent/JP2022501046A/ja
Publication of JP2022501046A5 publication Critical patent/JP2022501046A5/ja
Application granted granted Critical
Publication of JP7624388B2 publication Critical patent/JP7624388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021516368A 2018-09-24 2019-09-24 アルギナーゼ1ポリペプチド Active JP7624388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815549.9 2018-09-24
GBGB1815549.9A GB201815549D0 (en) 2018-09-24 2018-09-24 Arginase1 polypeptides
PCT/EP2019/075731 WO2020064744A1 (en) 2018-09-24 2019-09-24 Arginase1 polypeptides

Publications (3)

Publication Number Publication Date
JP2022501046A JP2022501046A (ja) 2022-01-06
JP2022501046A5 JP2022501046A5 (cg-RX-API-DMAC7.html) 2022-08-30
JP7624388B2 true JP7624388B2 (ja) 2025-01-30

Family

ID=64024184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516368A Active JP7624388B2 (ja) 2018-09-24 2019-09-24 アルギナーゼ1ポリペプチド

Country Status (12)

Country Link
US (2) US12194081B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856899A1 (cg-RX-API-DMAC7.html)
JP (1) JP7624388B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210091696A (cg-RX-API-DMAC7.html)
CN (1) CN112771159B (cg-RX-API-DMAC7.html)
AU (1) AU2019350356B9 (cg-RX-API-DMAC7.html)
CA (1) CA3113004A1 (cg-RX-API-DMAC7.html)
GB (1) GB201815549D0 (cg-RX-API-DMAC7.html)
IL (1) IL281762A (cg-RX-API-DMAC7.html)
MX (1) MX2021003441A (cg-RX-API-DMAC7.html)
SG (1) SG11202102378WA (cg-RX-API-DMAC7.html)
WO (1) WO2020064744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818576D0 (en) 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
US20250161422A1 (en) 2022-02-24 2025-05-22 Io Biotech Aps Arginase 2 vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160367648A1 (en) 2014-04-29 2016-12-22 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
WO2018065563A1 (en) 2016-10-07 2018-04-12 Herlev Hospital Immunogenic arginase peptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
WO2003038444A2 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
CA2836155A1 (en) 2004-10-29 2006-05-11 Board Of Trustees Of Michigan State University Protection against herbivores
PL3064579T3 (pl) 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
CN101781369A (zh) * 2009-01-20 2010-07-21 江苏先声药物研究有限公司 一种重组人精氨酸酶融合蛋白及其应用
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160367648A1 (en) 2014-04-29 2016-12-22 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
WO2018065563A1 (en) 2016-10-07 2018-04-12 Herlev Hospital Immunogenic arginase peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY,2017年12月26日,Vol. 7, No. 3, e1404215,pp. 1-9,https://doi.org/10.1080/2162402X.2017.1404215
ONCOIMMUNOLOGY,2018年07月23日,Vol. 7, No. 9, e1468957,pp. 1-8,https://doi.org/10.1080/2162402X.2018.1468957

Also Published As

Publication number Publication date
EP3856899A1 (en) 2021-08-04
AU2019350356B9 (en) 2026-01-29
MX2021003441A (es) 2021-06-15
WO2020064744A1 (en) 2020-04-02
US20250205318A1 (en) 2025-06-26
CN112771159A (zh) 2021-05-07
CA3113004A1 (en) 2020-04-02
US12194081B2 (en) 2025-01-14
JP2022501046A (ja) 2022-01-06
AU2019350356B2 (en) 2025-11-27
US20220031818A1 (en) 2022-02-03
AU2019350356A1 (en) 2021-04-15
GB201815549D0 (en) 2018-11-07
KR20210091696A (ko) 2021-07-22
CN112771159B (zh) 2025-02-11
AU2019350356A8 (en) 2021-05-27
SG11202102378WA (en) 2021-04-29
IL281762A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
US20250205318A1 (en) Arginase1 polypeptides
JP7758573B2 (ja) Tgf-ベータワクチン
US20250388674A1 (en) Immunogenic arginase 2 polypeptides
JP2019537562A (ja) 免疫原性アルギナーゼペプチド
US20250161422A1 (en) Arginase 2 vaccine
JP2025538981A (ja) TGF-β1ワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250120

R150 Certificate of patent or registration of utility model

Ref document number: 7624388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150